- Eiger BioPharmaceuticals' first approved therapy, Zokinvy (lonafarnib), for the treatment of ultra-rare Hutchinson-Gilford progeria syndrome, launched in January 2021.
- Lonafarnib – boosted by ritonavir – as well as the company’s clinical asset lambda, have demonstrated efficacy against hepatitis delta virus (Hep D) in Phase 2 trials.
- A recent acquisition in the Hep D space validates the significant opportunity for this indication, meriting a more thorough investigation of Eiger.
For further details see:
Evaluating An Investment In Eiger BioPharmaceuticals